FibroGen Inc (FGEN)
0.304
-0.02
(-5.68%)
USD |
NASDAQ |
Nov 05, 16:00
0.304
0.00 (0.00%)
After-Hours: 19:18
FibroGen Revenue (Quarterly): 50.64M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 50.64M |
| March 31, 2024 | 55.90M |
| December 31, 2023 | 27.14M |
| September 30, 2023 | 40.13M |
| June 30, 2023 | 44.32M |
| March 31, 2023 | 36.16M |
| December 31, 2022 | 34.37M |
| September 30, 2022 | 15.74M |
| June 30, 2022 | 29.81M |
| March 31, 2022 | 60.83M |
| December 31, 2021 | 16.54M |
| September 30, 2021 | 155.97M |
| June 30, 2021 | 24.36M |
| March 31, 2021 | 38.43M |
| December 31, 2020 | 65.00M |
| September 30, 2020 | 44.03M |
| June 30, 2020 | 42.89M |
| March 31, 2020 | 24.40M |
| December 31, 2019 | 7.974M |
| September 30, 2019 | 33.17M |
| June 30, 2019 | 191.57M |
| March 31, 2019 | 23.86M |
| Date | Value |
|---|---|
| December 31, 2018 | 108.06M |
| September 30, 2018 | 29.03M |
| June 30, 2018 | 43.95M |
| March 31, 2018 | 31.92M |
| December 31, 2017 | 30.74M |
| September 30, 2017 | 40.55M |
| June 30, 2017 | 30.27M |
| March 31, 2017 | 29.44M |
| December 31, 2016 | 35.52M |
| September 30, 2016 | 30.10M |
| June 30, 2016 | 89.28M |
| March 31, 2016 | 28.28M |
| December 31, 2015 | 24.44M |
| September 30, 2015 | 19.54M |
| June 30, 2015 | 120.55M |
| March 31, 2015 | 16.30M |
| December 31, 2014 | 16.10M |
| September 30, 2014 | 13.66M |
| June 30, 2014 | 89.96M |
| March 31, 2014 | 17.88M |
| December 31, 2013 | 12.39M |
| September 30, 2013 | 71.25M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.974M
Minimum
Dec 2019
155.97M
Maximum
Sep 2021
42.88M
Average
38.43M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Merck & Co Inc | 16.66B |
| Biomarin Pharmaceutical Inc | 745.74M |
| Arbutus Biopharma Corp | 1.726M |
| GlycoMimetics Inc | -- |
| Cidara Therapeutics Inc | 0.302M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -15.54M |
| Total Expenses (Quarterly) | 61.56M |
| EPS Diluted (Quarterly) | -0.16 |
| Enterprise Value | 6.090M |
| Gross Profit Margin (Quarterly) | 89.78% |
| Profit Margin (Quarterly) | -30.69% |
| Earnings Yield | -562.5% |
| Normalized Earnings Yield | -529.16 |